Pictet Asset Management Holding SA Sells 88,382 Shares of Grifols, S.A. (NASDAQ:GRFS)

Pictet Asset Management Holding SA decreased its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,626,603 shares of the biotechnology company's stock after selling 88,382 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.38% of Grifols worth $19,542,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank acquired a new stake in shares of Grifols during the fourth quarter valued at about $14,434,000. Whitebox Advisors LLC raised its holdings in Grifols by 56.2% in the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company's stock valued at $37,487,000 after buying an additional 1,519,093 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Grifols by 144.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock worth $17,782,000 after buying an additional 1,181,959 shares during the period. Brandes Investment Partners LP grew its holdings in Grifols by 3.0% during the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock worth $152,491,000 after acquiring an additional 592,096 shares during the last quarter. Finally, Barclays PLC increased its position in Grifols by 381.2% in the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock valued at $5,261,000 after acquiring an additional 469,401 shares during the period.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley began coverage on shares of Grifols in a report on Wednesday, February 12th. They set an "overweight" rating on the stock.

Grifols Trading Down 6.5 %

Shares of NASDAQ GRFS traded down $0.46 during trading on Friday, reaching $6.65. The company had a trading volume of 1,029,658 shares, compared to its average volume of 1,232,080. The stock has a market cap of $4.57 billion, a P/E ratio of 5.68 and a beta of 0.35. The company's fifty day moving average price is $7.53 and its 200-day moving average price is $7.97. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 12 month low of $5.79 and a 12 month high of $9.96.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.